Wendy Kan focuses her practice on corporate finance and capital markets. Her experience includes advising on Hong Kong initial public offerings, cross-border mergers and acquisitions, regulatory compliance, and general commercial matters.
ECM Transactions
- Folangsi Co., Ltd (2499.HK) in its HK$155 million (approximately US$20.15 million) IPO and listing on the Hong Kong Stock Exchange
- Beauty Farm Medical and Health Industry Inc. in its approximately US$100 million IPO and listing on the Hong Kong Stock Exchange
- Cryofocus Medtech (Shanghai) Co., Ltd. in its IPO and listing on the Hong Kong Stock Exchange
- OrbusNeich Medical Group in its US$62 million IPO and listing on the Hong Kong Stock Exchange
- Jenscare Scientific Co., Ltd. in its IPO and listing on the Hong Kong Stock Exchange
- RemeGen in its approximately US$412 million A-share IPO and listing on the Sci-Tech Innovation Board of the Shanghai Stock Exchange
- Shanghai Bio-heart Biological Technology Co., Ltd. in its US$65.3 million IPO and listing on the Hong Kong Stock Exchange
- OrbusNeich Medical Group in its US$200 million Series A and A-2 Fundraising Rounds
- Goldman Sachs (Asia) L.L.C. and China International Capital Corporation Hong Kong Securities Limited and other underwriters in the US$145 million IPO and listing of Shanghai HeartCare Medical Technology Corporation Limited on the Hong Kong Stock Exchange
- Brii Biosciences Limited in its US$318 million IPO and listing on the Hong Kong Stock Exchange
- Keymed Biosciences Inc. in its US$398 million IPO and listing on the Hong Kong Stock Exchange
- Fortune Financial Capital as sole sponsor, Fortune Securities, CICC as joint global coordinators and other underwriters in the US$56.8 million primary listing of Zero2IPO Holdings Inc. on the Hong Kong Stock Exchange
- JACOBIO Pharmaceuticals Group Co., Ltd. in its US$174 million IPO and listing on the Hong Kong Stock Exchange
- RemeGen Co., Ltd. in its US$515 million IPO and listing on the Hong Kong Stock Exchange
- Honliv Healthcare Management Group Company Limited in its US$41.3 million IPO and listing on the Hong Kong Stock Exchange
- Peijia Medical Limited in its US$343 million IPO and listing on the Hong Kong Stock Exchange
- Shanghai Kindly Medical Instrument Co., Ltd., in its US$106 million IPO and listing on the Hong Kong Stock Exchange
- Pharmaron in its approximately US$588 million dual primary listing and H share offering in Hong Kong
- China Securities (International) Corporate Finance Company Limited, as the sole sponsor and lead underwriter, in the US$133 million IPO of mobile game publisher FingerTango Inc.(6860.HK) on the Hong Kong Stock Exchange
- China Securities (International) Corporate Finance Company Limited, as the sole sponsor and lead underwriter, in the US$40 million IPO of mobile game publisher Digital Hollywood Interactive Limited (2022.HK) on the Hong Kong Stock Exchange
- Dexin China Holdings Company Limited (2019.HK) in its US$190 million IPO and listing on the Hong Kong Stock Exchange
- Shanghai Haohai Biological (6826.HK) in its US$300 million IPO and listing on the Hong Kong Stock Exchange
- Phoenix Healthcare Group Co. Ltd. in its HK$1.5 billion (US$190 million) IPO on the Main Board of the Hong Kong Stock Exchange
- Hengxing Gold Holding Company Limited in its HK$330 million (US$42.3 million) IPO on the Main Board of the Hong Kong Stock Exchange
- Representing a Beijing based hospital group in its proposed listing on the Main Board of the Hong Kong Stock Exchange
Corporate and M&A Transactions
- RemeGen in its exclusive worldwide license agreement with Seagen Inc.
- LifeTech Scientific Corporation in its issuance of convertible notes valued at HK$2 billion (US$281 million) as part of the strategic investment by Medtronic, Inc. (a Fortune 500 Company)
- a Korea based entertainment group in the acquisition of the entire equity interest of a Hong Kong private company. The private company is principally engaged in the entertainment business
- a PRC based mining company in the US$85 million pre-IPO investment by Deutsche Bank AG, Hong Kong Branch
- a shareholder of a NASDAQ-listed company engaging in the business of producing and selling a wide variety of fruit products in its first round of financing through subscription of exchange bonds and preferred shares. The investors include sovereign funds and a state-owned bank
DCM Transactions
- China Eastern Airline in connection with its “dim sum” bond offering of RMB2.2 billion 3.875% guaranteed bonds and a tap issue of RMB800 million 4.8% guaranteed bonds
Languages
- Mandarin Chinese
- Cantonese
Admissions
Bar Admissions
- Hong Kong
Education
- University of Hong Kong, PCLL; LLB
Professional Activities
Member
- Hong Kong Law Society
Related Practices
Related Regions